Skip to content

Cellectar Biosciences, Inc.: 10-Q filed 2026-05-14

What Cellectar Biosciences, Inc. reported in its quarterly report filed 2026-05-14 (fiscal Q1 2026): 28 published measures, 57 facts as tagged in accession 0001104659-26-060678.

This filing

Form
10-Q (quarterly report)
Filed
2026-05-14
Fiscal period
fiscal Q1 2026
Accession
0001104659-26-060678 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Cellectar Biosciences, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2026-03-3111,119,761USD
At 2025-12-3114,978,321USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2026-03-316,402,651USD
At 2025-12-315,059,134USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2026-03-313,335,087USD
At 2025-12-318,537,164USD
At 2025-03-318,253,389USD
At 2024-12-3114,294,681USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2026-03-318,347,090USD
At 2025-12-3113,196,033USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2026-01-01 to 2026-03-31-5,653,946USD90
2025-01-01 to 2025-03-31-6,604,029USD90

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2026-01-01 to 2026-03-31-4,845,565USD90
2025-01-01 to 2025-03-31-9,383,434USD90

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2026-01-01 to 2026-03-313,378USD90

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2026-01-01 to 2026-03-31-3,378USD90

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2026-03-31-274,787,446USD
At 2025-12-31-269,133,500USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2026-01-01 to 2026-03-314,240,129shares90
2025-01-01 to 2025-03-311,535,995shares90

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2026-01-01 to 2026-03-314,240,129shares90
2025-01-01 to 2025-03-311,535,995shares90

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2026-01-01 to 2026-03-31-1.33USD/shares90
2025-01-01 to 2025-03-31-4.3USD/shares90

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2026-01-01 to 2026-03-31-1.33USD/shares90
2025-01-01 to 2025-03-31-4.3USD/shares90

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2026-03-31339,697USD
At 2025-12-31549,405USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2026-01-01 to 2026-03-31451,869USD90
2025-01-01 to 2025-03-31562,737USD90

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2026-01-01 to 2026-03-31-5,793,942USD90
2025-01-01 to 2025-03-31-6,400,991USD90

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2026-03-319,267,128USD
At 2025-12-3114,038,465USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2026-03-314,873,826USD
At 2025-12-314,749,737USD

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2026-01-01 to 2026-03-313,007,229USD90
2025-01-01 to 2025-03-313,427,095USD90

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2026-03-314,240,129shares
At 2025-12-314,240,129shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2026-03-318,347,090USD
At 2025-12-3113,196,033USD
At 2025-03-3113,905,173USD
At 2024-12-3123,288,607USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2026-03-31277,601,713USD
At 2025-12-31277,149,844USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2026-03-311,483,156USD
At 2025-12-31360,671USD

Operating lease liability

Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.

PeriodValueUnitDays
At 2026-03-311,529,000USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2026-03-3129,780USD
At 2025-12-3129,780USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2026-03-31920,038USD
At 2025-12-31842,432USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2026-01-01 to 2026-03-312,786,713USD90
2025-01-01 to 2025-03-312,973,896USD90

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2026-01-01 to 2026-03-31139,996USD90
2025-01-01 to 2025-03-31-203,038USD90

Inspect the source

Entity
Cellectar Biosciences, Inc. / CIK 0001279704
Captured
2026-09-20T07:48:31.991Z
SEC response SHA-256
44da00fed89c835867d9290b98319109f07ad849957763fd081353f99891a212

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001279704.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))